Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University is the lead sponsor of 31 current clinical trials in our China register. 15 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Tislelizumab, Azacytidine and Cetuximab. The most-studied condition is Preterm.

ClinicalTrials.gov trials by status

Recruiting1548%
Not yet open1342%
Active, closed310%

Trials by phase

Observational1342%
Not applicable723%
Phase 2723%
Phase 126%
Phase 413%
Phase EARLY_PHASE113%

Clinical trials sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

31 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Single-port Versus Multi-port Robotic Surgery for Rectal Cancer NCT06824688 · ClinicalTrials.gov ↗ · Rectal Cancer Patients, Robotic Surgical Procedures	Not applicable	Recruiting	2025-04	China
Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma NCT07468630 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma Drug: Sintilimab	Phase 2	Recruiting	2026-04	China
Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis NCT06882811 · ClinicalTrials.gov ↗ · Sepsis	Phase EARLY_PHASE1	Recruiting	2025-05	China
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY NCT06354140 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	2024-05	China
Single-port Robotic Radical Gastrectomy for Gastric Cancer NCT07237126 · ClinicalTrials.gov ↗ · Gastric Cancer Patients Undergoing Gastrectomy	Not applicable	Recruiting	2026-07	China
Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas NCT07405372 · ClinicalTrials.gov ↗ · Glioma	Observational	Recruiting	2025-12	China
Application of FAPI and FDG PET Imaging in Patients With Different Types of Cancer NCT06284070 · ClinicalTrials.gov ↗ · Cancer	Observational	Recruiting	2024-01	China
High-Frequency Oscillation Ventilation Versus Conventional Mechanical Ventilation in Very Preterm Infants With Perinatal Acute Respiratory Distress Syndrome: Multicenters Randomized Controlled, Superiority Trial NCT03736707 · ClinicalTrials.gov ↗ · Acute Respiratory Distress Syndrome, High Frequency Oscillatory Ventilation, Preterm	Not applicable	Recruiting	2025-10	China
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis NCT06848465 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastasis, LDRT Drugs: Tislelizumab, Xelox	Phase 1	Recruiting	2025-02	China
Surfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS) NCT04777760 · ClinicalTrials.gov ↗ · Respiratory Distress Syndrome, Preterm Birth, Acute Respiratory Distress Syndrome	Observational	Recruiting	2021-01	China
Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging NCT06945549 · ClinicalTrials.gov ↗ · Inflammatory Bowel Disease (IBD), Disease Activity, FAPI	Observational	Recruiting	2025-04	China
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer NCT06709885 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma	Phase 2	Recruiting	2024-10	China
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC NCT06978829 · ClinicalTrials.gov ↗ · LA HNSCC Drugs: Cetuximab, Tislelizumab	Phase 2	Recruiting	2025-03	China
Virtual Ileostomy Versus Diverting Ileostomy in Patients Undergoing Total Mesorectal Excision NCT06633133 · ClinicalTrials.gov ↗ · Rectal Cancer	Not applicable	Recruiting	2024-10	China
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) NCT07165847 · ClinicalTrials.gov ↗ · Immunotherapy, Gastric Cancer (GC), Radiotherapy Drugs: Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur	Phase 2	Recruiting	2025-07	China
Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery NCT07354698 · ClinicalTrials.gov ↗ · Papillary Thyroid Cancer	Phase 4	Not yet open	2026-02	China
Clinical Study of Trap-(FAPI)3 PET Imaging in the Diagnosis of Pulmonary Nodules NCT07448441 · ClinicalTrials.gov ↗ · Lung Nodules	Observational	Not yet open	2026-03	China
LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer NCT07453875 · ClinicalTrials.gov ↗ · Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT	Phase 1	Not yet open	2026-05	China
Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy NCT07376876 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer	Phase 2	Not yet open	2026-01	China
AZA Combined with R-GemOx for Elderly DLBCL Patients NCT06778902 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma Drugs: Azacytidine, R-GemOx	Phase 2	Not yet open	2025-02	China
Enteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung Cancer NCT07035444 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Cachexia	Not applicable	Not yet open	2025-06	China
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment NCT07459179 · ClinicalTrials.gov ↗ · Interstitial Lung Disease	Observational	Not yet open	2026-04	China
Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors NCT07128277 · ClinicalTrials.gov ↗ · Cancer	Observational	Not yet open	2025-08	China
Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer NCT07185308 · ClinicalTrials.gov ↗ · Cachexia; Cancer	Not applicable	Not yet open	2025-11	China
Artificial Intelligence Model-Assisted Accurate Diagnosis of Early-Stage Breast Cancer NCT07063667 · ClinicalTrials.gov ↗ · Breast Cancer, Metastatic, Artifical Intelligence	Observational	Not yet open	2025-08	China
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases NCT07459205 · ClinicalTrials.gov ↗ · Pulmonary Fibrosis	Observational	Not yet open	2026-03	China
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors NCT07459192 · ClinicalTrials.gov ↗ · Canser	Observational	Not yet open	2026-04	China
Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging NCT07440212 · ClinicalTrials.gov ↗ · Esophagus Cancer	Observational	Not yet open	2026-02	China
CT and Endoscopic Biopsy Image-Based Deep Learning for Predicting Left Recurrent Laryngeal Nerve Lymph Node Metastasis in Esophageal Cancer NCT07074535 · Esophageal Squamous Cell Cancer (SCC), Recurrent Laryngeal Nerve Palsy, Deep Learning	Observational	Active, closed	2019-01	China
Milk Temperature Control and Necrotizing Enterocolitis Risk in Extremely Preterm Infants NCT06908239 · ClinicalTrials.gov ↗ · Necrotizing Enterocolitis, Preterm	Not applicable	Active, closed	2024-09	China
Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study NCT06950164 · ClinicalTrials.gov ↗ · Preterm, Ductus Arteriosus	Observational	Active, closed	2025-04	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials

9 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Tislelizumab2 Azacytidine1 Cetuximab1 Iparomlimab and Tuvonralimab1 Oxaliplatin1 R-GemOx1 Sintilimab1 Tegafur1 Xelox1

Conditions in Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials

48 conditions

Preterm3Colon Adenocarcinoma2LDRT2Cancer2 Acute Respiratory Distress Syndrome2Esophageal Squamous Cell Cancer (SCC)1Recurrent Laryngeal Nerve Palsy1Deep Learning1Postoperative Complication1Papillary Thyroid Cancer1Rectal Cancer Patients1Robotic Surgical Procedures1Sepsis1Lung Nodules1Esophageal Squamous Cell Carcinoma1Necrotizing Enterocolitis1Ductus Arteriosus1Gastric Cancer Patients Undergoing Gastrectomy1Peritoneal Metastasis of Gastric and Colorectal Cancer1Esophageal Squamous Cell Carcinoma (ESCC)1 Esophageal Cancer1 Glioma1High Frequency Oscillatory Ventilation1Conventional Mechanical Ventilation1

By trial register

Register	Trials	Recruiting
Clinical trials in China	31	15

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Preterm

Sponsor	Trials
Nemours Children's Clinic	1

Sponsors with the most current trials registered for this condition.

Questions about Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials

How many clinical trials does Daping Hospital and the Research Institute of Surgery of the Third Military Medical University sponsor?

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University is the lead sponsor of 31 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials recruiting?

Yes. 15 of its 31 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Daping Hospital and the Research Institute of Surgery of the Third Military Medical University testing?

Its current trials name 9 drugs and biologicals as interventions. The most frequent are Tislelizumab (2), Azacytidine (1), Cetuximab (1), Iparomlimab and Tuvonralimab (1) and Oxaliplatin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University clinical trials